{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:20:02Z","timestamp":1768566002192,"version":"3.49.0"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00262-022-03142-3","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T08:03:00Z","timestamp":1644220980000},"page":"2077-2098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adoptive cell therapies in thoracic malignancies"],"prefix":"10.1007","volume":"71","author":[{"given":"Julie","family":"Lasvergnas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Naigeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kader","family":"Chouahnia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Zelek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Chaput","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0872-2983","authenticated-orcid":false,"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"3142_CR1","doi-asserted-by":"crossref","unstructured":"Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Prev Biomark. Am Assoc Cancer Res 28:1563\u20131579.","DOI":"10.1158\/1055-9965.EPI-19-0221"},{"key":"3142_CR2","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","volume":"25","author":"DB Doroshow","year":"2019","unstructured":"Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L et al (2019) Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res Off J Am Assoc Cancer Res 25:4592\u20134602","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3142_CR3","doi-asserted-by":"crossref","unstructured":"Remon J, Aldea M, Besse B, Planchard D, Reck M, Giaccone G et al (2021) Small cell lung cancer: a slightly less orphan disease after immunotherapy. Ann Oncol Off J Eur Soc Med Oncol.","DOI":"10.1016\/j.annonc.2021.02.025"},{"key":"3142_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, D\u00f4 P, Bylicki O et al (2019) Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20:239\u2013253","journal-title":"Lancet Oncol"},{"key":"3142_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS et al (2021) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet Lond Engl 397:375\u2013386","journal-title":"Lancet Lond Engl"},{"key":"3142_CR6","doi-asserted-by":"publisher","unstructured":"Wang F, Wang S, Zhou Q (2020) The resistance mechanisms of lung cancer immunotherapy. Front Oncol [Internet]. Frontiers; 2020 [cited 2021 Marcs 21];10. https:\/\/doi.org\/10.3389\/fonc.2020.568059\/full","DOI":"10.3389\/fonc.2020.568059\/full"},{"key":"3142_CR7","doi-asserted-by":"crossref","unstructured":"Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18:197\u2013218.","DOI":"10.1038\/s41573-018-0007-y"},{"key":"3142_CR8","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41591-020-0900-x","volume":"26","author":"K AbdulJabbar","year":"2020","unstructured":"AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A et al (2020) Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med 26:1054\u20131062","journal-title":"Nat Med"},{"key":"3142_CR9","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463\u20131469","journal-title":"Science"},{"key":"3142_CR10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571","journal-title":"Nature"},{"key":"3142_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W et al (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249\u2013253","journal-title":"Nature"},{"key":"3142_CR12","doi-asserted-by":"publisher","first-page":"1886726","DOI":"10.1080\/2162402X.2021.1886726","volume":"10","author":"G Bindea","year":"2021","unstructured":"Bindea G, Mlecnik B, Galon J (2021) Expand to shield: IL-15 and in situ lymphocytic proliferation. Oncoimmunology 10:1886726","journal-title":"Oncoimmunology"},{"key":"3142_CR13","doi-asserted-by":"crossref","unstructured":"Domen A, Quatannens D, Zanivan S, Deben C, Van Audenaerde J, Smits E et al (2021) Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer. Cancers, 13.","DOI":"10.3390\/cancers13050987"},{"key":"3142_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707\u2013723","journal-title":"Cell"},{"key":"3142_CR15","doi-asserted-by":"crossref","unstructured":"Koulouris A, Tsagkaris C, Nikolaou M (2021) Real impact of novel immunotherapy drugs in cancer. The Experience of 10 Last Years. Toxins, p 13.","DOI":"10.3390\/toxins13020149"},{"key":"3142_CR16","doi-asserted-by":"crossref","unstructured":"Gaissmaier L, Christopoulos P (2020) Immune modulation in lung cancer: current concepts and future strategies. Respir Int Rev Thorac Dis, pp 1\u201327.","DOI":"10.1159\/000510385"},{"key":"3142_CR17","doi-asserted-by":"crossref","unstructured":"Kim JY, Lee KH, Eisenhut M, van der Vliet HJ, Kronbichler A, Jeong GH et al (2019) Efficacy of cancer immunotherapy: an umbrella review of meta-analyses of randomized controlled trials. Cancers [Internet]. 2019 [cited 2021 Mar 18];11. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6895783\/","DOI":"10.3390\/cancers11111801"},{"key":"3142_CR18","doi-asserted-by":"crossref","unstructured":"Yu JX, Hubbard-Lucey VM, Tang J (2019) The global pipeline of cell therapies for cancer. Nat Rev Drug Discov 18:821\u2013822.","DOI":"10.1038\/d41573-019-00090-z"},{"key":"3142_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fimmu.2015.00230","volume":"6","author":"G Pittari","year":"2015","unstructured":"Pittari G, Filippini P, Gentilcore G, Grivel J-C, Rutella S (2015) Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Front Immunol 6:230","journal-title":"Front Immunol"},{"key":"3142_CR20","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485\u20131492","journal-title":"N Engl J Med"},{"key":"3142_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H","volume":"80","author":"H Kimura","year":"1997","unstructured":"Kimura H, Yamaguchi Y (1997) A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80:42\u201349","journal-title":"Cancer"},{"key":"3142_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0169-5002(99)00082-3","volume":"26","author":"T Yano","year":"1999","unstructured":"Yano T, Sugio K, Yamazaki K, Kase S, Yamaguchi M, Ondo K et al (1999) Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer Amst Neth 26:143\u2013148","journal-title":"Lung Cancer Amst Neth"},{"key":"3142_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139\u2013149","journal-title":"J Exp Med"},{"key":"3142_CR24","doi-asserted-by":"publisher","first-page":"9291","DOI":"10.1002\/jcp.29827","volume":"235","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Schmidt-Wolf IGH (2020) Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol 235:9291\u20139303","journal-title":"J Cell Physiol"},{"key":"3142_CR25","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3389\/fimmu.2017.00774","volume":"8","author":"X Gao","year":"2017","unstructured":"Gao X, Mi Y, Guo N, Xu H, Xu L, Gou X et al (2017) Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. Front Immunol 8:774","journal-title":"Front Immunol"},{"key":"3142_CR26","doi-asserted-by":"crossref","unstructured":"Garofano F, Gonzalez-Carmona MA, Skowasch D, Schmidt-Wolf R, Abramian A, Hauser S et al (2019) Clinical trials with combination of cytokine-induced killer cells and dendritic cells for cancer therapy. Int J Mol Sci [Internet]. 2019 [cited 2021 Mar 31];20. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6747410\/","DOI":"10.3390\/ijms20174307"},{"issue":"35","key":"3142_CR27","first-page":"337","volume":"2012","author":"G Lin","year":"1997","unstructured":"Lin G, Wang J, Lao X, Wang J, Li L, Li S et al (1997) Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother Hagerstown Md 2012(35):337\u2013343","journal-title":"J Immunother Hagerstown Md"},{"key":"3142_CR28","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1006\/cyto.2000.0733","volume":"12","author":"B Zoll","year":"2000","unstructured":"Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt-Wolf IG (2000) Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine 12:1385\u20131390","journal-title":"Cytokine"},{"key":"3142_CR29","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jcyt.2014.01.070","volume":"16","author":"P Iudicone","year":"2014","unstructured":"Iudicone P, Fioravanti D, Cicchetti E, Bonanno G, Pandolfi A, Scocchera R et al (2014) Cytotoxic potential of interleukin-15 stimulated cytokine induced killer (CIK) against epithelial cancer cell lines. Cytotherapy 16:S23","journal-title":"Cytotherapy"},{"key":"3142_CR30","first-page":"3997","volume":"28","author":"C Wu","year":"2008","unstructured":"Wu C, Jiang J, Shi L, Xu N (2008) Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 28:3997\u20134002","journal-title":"Anticancer Res"},{"key":"3142_CR31","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00262-012-1260-2","volume":"61","author":"R Li","year":"2012","unstructured":"Li R, Wang C, Liu L, Du C, Cao S, Yu J et al (2012) Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother CII 61:2125\u20132133","journal-title":"Cancer Immunol Immunother CII"},{"key":"3142_CR32","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.7314\/APJCP.2014.15.15.6009","volume":"15","author":"C Jin","year":"2014","unstructured":"Jin C, Li J, Wang Y, Chen X, Che Y, Liu X et al (2014) Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy. Asian Pac J Cancer Prev APJCP 15:6009\u20136014","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"3142_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.intimp.2010.12.014","volume":"11","author":"Q Niu","year":"2011","unstructured":"Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G et al (2011) Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 11:449\u2013456","journal-title":"Int Immunopharmacol"},{"key":"3142_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.intimp.2018.06.012","volume":"61","author":"Z Xiao","year":"2018","unstructured":"Xiao Z, Wang C-Q, Zhou M-H, Li N-N, Liu S-Y, He Y-J et al (2018) Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: a meta-analysis of 16 randomized controlled trials. Int Immunopharmacol 61:363\u2013375","journal-title":"Int Immunopharmacol"},{"key":"3142_CR35","first-page":"406","volume":"9","author":"L Zhang","year":"2019","unstructured":"Zhang L, Xu Z, Chen X, Duan Y, Chen Z, Sun J (2019) Clinical benefits of Livin peptide-loaded DCs\/CIKs combined with chemotherapy in advanced non-small cell lung cancer. Am J Cancer Res 9:406\u2013414","journal-title":"Am J Cancer Res"},{"issue":"37","key":"3142_CR36","first-page":"250","volume":"2014","author":"S-B Shi","year":"1997","unstructured":"Shi S-B, Tang X-Y, Tian J, Chang C-X, Li P, Qi J-L (1997) Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer. J Immunother Hagerstown Md 2014(37):250\u2013255","journal-title":"J Immunother Hagerstown Md"},{"key":"3142_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan MG, Lanier LL (2016) NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16:7\u201319","journal-title":"Nat Rev Cancer"},{"key":"3142_CR38","doi-asserted-by":"crossref","unstructured":"Nersesian S, Schwartz SL, Grantham SR, MacLean LK, Lee SN, Pugh-Toole M et al (2021) NK cell infiltration is associated with improved overall survival in solid cancers: a systematic review and meta-analysis. Transl Oncol 14:100930.","DOI":"10.1016\/j.tranon.2020.100930"},{"key":"3142_CR39","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19:200\u2013218","journal-title":"Nat Rev Drug Discov"},{"key":"3142_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","volume":"107","author":"YT Bryceson","year":"2006","unstructured":"Bryceson YT, March ME, Ljunggren H-G, Long EO (2006) Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107:159\u2013166","journal-title":"Blood"},{"key":"3142_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","volume":"33","author":"KC Conlon","year":"2015","unstructured":"Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC et al (2015) Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 33:74\u201382","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3142_CR42","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1084\/jem.20120944","volume":"209","author":"J Ni","year":"2012","unstructured":"Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A (2012) Sustained effector function of IL-12\/15\/18-preactivated NK cells against established tumors. J Exp Med 209:2351\u20132365","journal-title":"J Exp Med"},{"issue":"162","key":"3142_CR43","first-page":"4511","volume":"1999","author":"TA Fehniger","year":"1950","unstructured":"Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA et al (1950) Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol Baltim Md 1999(162):4511\u20134520","journal-title":"J Immunol Baltim Md"},{"key":"3142_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/35040504","volume":"408","author":"J Parrish-Novak","year":"2000","unstructured":"Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA et al (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57\u201363","journal-title":"Nature"},{"key":"3142_CR45","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/eji.201344272","volume":"44","author":"M Vitale","year":"2014","unstructured":"Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L (2014) Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol 44:1582\u20131592","journal-title":"Eur J Immunol"},{"key":"3142_CR46","doi-asserted-by":"crossref","unstructured":"Poznanski SM, Ritchie TM, Fan IY, El-Sayes A, Portillo AL, Ben-Avi R et al (2021)Expanded human NK cells from lung cancer patients sensitize patients\u2019 PDL1-negative tumors to PD1-blockade therapy. J Immunother Cancer, p 9.","DOI":"10.1136\/jitc-2020-001933"},{"key":"3142_CR47","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1182\/blood-2008-06-165225","volume":"113","author":"PS Woll","year":"2009","unstructured":"Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR et al (2009) Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113:6094\u20136101","journal-title":"Blood"},{"key":"3142_CR48","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","volume":"105","author":"JS Miller","year":"2005","unstructured":"Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051\u20133057","journal-title":"Blood"},{"key":"3142_CR49","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00262-010-0904-3","volume":"59","author":"EG Iliopoulou","year":"2010","unstructured":"Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN et al (2010) A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother CII 59:1781\u20131789","journal-title":"Cancer Immunol Immunother CII"},{"key":"3142_CR50","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1172\/JCI132712","volume":"130","author":"M Lin","year":"2020","unstructured":"Lin M, Luo H, Liang S, Chen J, Liu A, Niu L et al (2020) Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest 130:2560\u20132569","journal-title":"J Clin Invest"},{"key":"3142_CR51","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s12026-017-8927-x","volume":"65","author":"M Lin","year":"2017","unstructured":"Lin M, Liang S-Z, Wang X-H, Liang Y-Q, Zhang M-J, Niu L-Z et al (2017) Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res 65:880\u2013887","journal-title":"Immunol Res"},{"key":"3142_CR52","doi-asserted-by":"crossref","unstructured":"Franks SE, Wolfson B, Hodge JW (2020) Natural born killers: NK cells in cancer therapy. Cancers [Internet]. 2020 [cited 2021 Apr 4];12. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7465121\/","DOI":"10.3390\/cancers12082131"},{"key":"3142_CR53","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U et al (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15:1563\u20131570","journal-title":"Cytotherapy"},{"key":"3142_CR54","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-20-1141","volume":"26","author":"G Multhoff","year":"2020","unstructured":"Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C et al (2020) Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: a randomized Phase II Clinical Trial. Clin Cancer Res Off J Am Assoc Cancer Res 26:5368\u20135379","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3142_CR55","doi-asserted-by":"publisher","first-page":"e15024","DOI":"10.1200\/JCO.2020.38.15_suppl.e15024","volume":"38","author":"SP Chawla","year":"2020","unstructured":"Chawla SP, Kim KM, Chua VS, Jafari O, Song PY (2020) Phase I study of SNK01 (autologous non-genetically modified natural killer cells with enhanced cytotoxicity) in refractory metastatic solid tumors. J Clin Oncol 38:e15024\u2013e15024","journal-title":"J Clin Oncol"},{"key":"3142_CR56","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.2020.38.15_suppl.3037","volume":"38","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, Ko D-H, Ji W, Rho JK, Lee JC, Song PY et al (2020) A randomized phase I\/IIa study to evaluate the safety and efficacy of SNK01 (non-genetically modified autologous natural killer cells with enhanced cytotoxicity) plus pembrolizumab in patients with stage IV non-small cell lung cancer. J Clin Oncol 38:3037\u20133037","journal-title":"J Clin Oncol"},{"key":"3142_CR57","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1200\/JCO.1988.6.5.839","volume":"6","author":"SL Topalian","year":"1988","unstructured":"Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM et al (1988) Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol Off J Am Soc Clin Oncol 6:839\u2013853","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3142_CR58","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res 17:4550\u20134557","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3142_CR59","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","volume":"30","author":"U Dafni","year":"2019","unstructured":"Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D et al (2019) Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol 30:1902\u20131913","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3142_CR60","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni Y, Becht E, Fehlings M, Loh CY, Koo S-L, Teng KWW et al (2018) Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557:575\u2013579","journal-title":"Nature"},{"key":"3142_CR61","doi-asserted-by":"crossref","unstructured":"Janelle V, Delisle J-S (2021) T-Cell Dysfunction as a limitation of adoptive immunotherapy: current concepts and mitigation strategies. Cancers [Internet]. 2021 [cited 2021 Apr 5];13. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7913380\/","DOI":"10.3390\/cancers13040598"},{"key":"3142_CR62","doi-asserted-by":"crossref","unstructured":"Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM et al (2021) Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer, pp 1\u201318.","DOI":"10.1038\/s41416-021-01353-6"},{"key":"3142_CR63","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","volume":"9","author":"T Duhen","year":"2018","unstructured":"Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF et al (2018) Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun 9:2724","journal-title":"Nat Commun"},{"key":"3142_CR64","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3389\/fimmu.2020.00340","volume":"11","author":"A Martinez-Usatorre","year":"2020","unstructured":"Martinez-Usatorre A, Carmona SJ, Godfroid C, Yacoub Maroun C, Labiano S, Romero P (2020) Enhanced Phenotype definition for precision isolation of precursor exhausted tumor-infiltrating CD8 T cells. Front Immunol 11:340","journal-title":"Front Immunol"},{"key":"3142_CR65","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ncponc0666","volume":"3","author":"P Muranski","year":"2006","unstructured":"Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R et al (2006) Increased intensity lymphodepletion and adoptive immunotherapy\u2013-how far can we go? Nat Clin Pract Oncol 3:668\u2013681","journal-title":"Nat Clin Pract Oncol"},{"key":"3142_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","volume":"348","author":"SA Rosenberg","year":"2015","unstructured":"Rosenberg SA, Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348:62\u201368","journal-title":"Science"},{"issue":"191","key":"3142_CR67","first-page":"3955","volume":"2013","author":"SR Pedersen","year":"1950","unstructured":"Pedersen SR, S\u00f8rensen MR, Buus S, Christensen JP, Thomsen AR (1950) Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. J Immunol Baltim Md 2013(191):3955\u20133967","journal-title":"J Immunol Baltim Md"},{"key":"3142_CR68","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0140-6736(89)91609-7","volume":"1","author":"RL Kradin","year":"1989","unstructured":"Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE et al (1989) Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet Lond Engl 1:577\u2013580","journal-title":"Lancet Lond Engl"},{"key":"3142_CR69","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<244::AID-CNCR9>3.0.CO;2-L","volume":"78","author":"GB Ratto","year":"1996","unstructured":"Ratto GB, Zino P, Mirabelli S, Minuti P, Aquilina R, Fantino G et al (1996) A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 78:244\u2013251","journal-title":"Cancer"},{"key":"3142_CR70","doi-asserted-by":"crossref","unstructured":"Chesney JA, Lutzky J, Thomas SS, Nieva JJ, Munoz Couselo E, Martin-Liberal J et al (2019) A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144\/LN-145) in patients with solid tumors. J Clin Oncol 37:TPS2648\u2013TPS2648.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2648"},{"key":"3142_CR71","doi-asserted-by":"publisher","first-page":"S800","DOI":"10.1016\/S1556-0864(21)02030-X","volume":"16","author":"E Massarelli","year":"2021","unstructured":"Massarelli E, Goldberg Z, Cacovean A, Yadav B, Chen G, Jagasia M et al (2021) 188TiP A phase II multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN-145) cell therapy in patients with metastatic non-small cell lung cancer (mNSCLC). J Thorac Oncol 16:S800","journal-title":"J Thorac Oncol"},{"key":"3142_CR72","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","volume":"27","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S et al (2021) Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med 27:1410\u20131418","journal-title":"Nat Med"},{"key":"3142_CR73","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/mc.23193","volume":"59","author":"MJ Besser","year":"2020","unstructured":"Besser MJ, Itzhaki O, Ben-Betzalel G, Zippel DB, Zikich D, Kubi A et al (2020) Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. Mol Carcinog 59:736\u2013744","journal-title":"Mol Carcinog"},{"key":"3142_CR74","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00262-018-2174-4","volume":"67","author":"R Ben-Avi","year":"2018","unstructured":"Ben-Avi R, Farhi R, Ben-Nun A, Gorodner M, Greenberg E, Markel G et al (2018) Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. Cancer Immunol Immunother CII 67:1221\u20131230","journal-title":"Cancer Immunol Immunother CII"},{"key":"3142_CR75","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00251-008-0303-5","volume":"60","author":"R Carretero","year":"2008","unstructured":"Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM et al (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60:439\u2013447","journal-title":"Immunogenetics"},{"key":"3142_CR76","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.18632\/oncotarget.23469","volume":"9","author":"F Perea","year":"2018","unstructured":"Perea F, S\u00e1nchez-Palencia A, G\u00f3mez-Morales M, Bernal M, Concha \u00c1, Garc\u00eda MM et al (2018) HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape. Oncotarget 9:4120\u20134133","journal-title":"Oncotarget"},{"key":"3142_CR77","doi-asserted-by":"crossref","unstructured":"Pulido M, Chamorro V, Romero I, Algarra I, S-Montalvo A, Collado A et al (2020) Restoration of MHC-I on tumor cells by fhit transfection promotes immune rejection and acts as an individualized immunotherapeutic vaccine. Cancers, 12.","DOI":"10.3390\/cancers12061563"},{"key":"3142_CR78","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F et al (2017) Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun 8:1738","journal-title":"Nat Commun"},{"issue":"192","key":"3142_CR79","first-page":"1286","volume":"2014","author":"A Arina","year":"1950","unstructured":"Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H (1950) Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol Baltim Md 2014(192):1286\u20131293","journal-title":"J Immunol Baltim Md"},{"key":"3142_CR80","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.coi.2015.02.006","volume":"33","author":"A Arina","year":"2015","unstructured":"Arina A, Bronte V (2015) Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Curr Opin Immunol 33:120\u2013125","journal-title":"Curr Opin Immunol"},{"key":"3142_CR81","doi-asserted-by":"crossref","unstructured":"Stevens D, Ingels J, Van Lint S, Vandekerckhove B, Vermaelen K (2020) Dendritic cell-based immunotherapy in lung cancer. Front Immunol 11:620374.","DOI":"10.3389\/fimmu.2020.620374"},{"key":"3142_CR82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00262-019-02448-z","volume":"69","author":"R Zhang","year":"2020","unstructured":"Zhang R, Yuan F, Shu Y, Tian Y, Zhou B, Yi L et al (2020) Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Cancer Immunol Immunother CII 69:135\u2013145","journal-title":"Cancer Immunol Immunother CII"},{"key":"3142_CR83","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/7403","volume":"5","author":"NC Fernandez","year":"1999","unstructured":"Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M et al (1999) Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5:405\u2013411","journal-title":"Nat Med"},{"key":"3142_CR84","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1093\/annonc\/mdv323","volume":"26","author":"A Thomas","year":"2015","unstructured":"Thomas A, Giaccone G (2015) Why has active immunotherapy not worked in lung cancer? Ann Oncol Off J Eur Soc Med Oncol 26:2213\u20132220","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3142_CR85","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fimmu.2014.00147","volume":"5","author":"RR Laborde","year":"2014","unstructured":"Laborde RR, Lin Y, Gustafson MP, Bulur PA, Dietz AB (2014) Cancer vaccines in the world of immune suppressive monocytes (CD14(+)HLA-DR(lo\/neg) Cells): the gateway to improved responses. Front Immunol 5:147","journal-title":"Front Immunol"},{"key":"3142_CR86","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1158\/1078-0432.CCR-08-2982","volume":"15","author":"A Bonehill","year":"2009","unstructured":"Bonehill A, Van Nuffel AMT, Corthals J, Tuyaerts S, Heirman C, Francois V et al (2009) Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res Off J Am Assoc Cancer Res 15:3366\u20133375","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3142_CR87","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S et al (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature Nature Publishing Group 515:572\u2013576","journal-title":"Nature"},{"key":"3142_CR88","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ et al (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547:217\u2013221","journal-title":"Nature"},{"key":"3142_CR89","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","volume":"6","author":"Z Ding","year":"2021","unstructured":"Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S et al (2021) Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal Transduct Target Ther 6:26","journal-title":"Signal Transduct Target Ther"},{"key":"3142_CR90","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/cncr.20843","volume":"103","author":"G-C Chang","year":"2005","unstructured":"Chang G-C, Lan H-C, Juang S-H, Wu Y-C, Lee H-C, Hung Y-M et al (2005) A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 103:763\u2013771","journal-title":"Cancer"},{"key":"3142_CR91","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2010.02.006","volume":"70","author":"S-J Um","year":"2010","unstructured":"Um S-J, Choi YJ, Shin H-J, Son CH, Park Y-S, Roh MS et al (2010) Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer Amst Neth 70:188\u2013194","journal-title":"Lung Cancer Amst Neth"},{"key":"3142_CR92","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","volume":"193","author":"R Cornelissen","year":"2016","unstructured":"Cornelissen R, Hegmans JPJJ, Maat APWM, Kaijen-Lambers MEH, Bezemer K, Hendriks RW et al (2016) Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med 193:1023\u20131031","journal-title":"Am J Respir Crit Care Med"},{"key":"3142_CR93","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","volume":"24","author":"JGJV Aerts","year":"2018","unstructured":"Aerts JGJV, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH et al (2018) Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin Cancer Res 24:766\u2013776","journal-title":"Clin Cancer Res"},{"key":"3142_CR94","doi-asserted-by":"crossref","unstructured":"on behalf of the DENIM team*, Belderbos RA, Baas P, Berardi R, Cornelissen R, Fennell DA et al (2019) A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. Transl Lung Cancer Res 8:280\u2013285.","DOI":"10.21037\/tlcr.2019.05.05"},{"key":"3142_CR95","doi-asserted-by":"crossref","unstructured":"de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE (2019) Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. BMJ Open 9:e026779.","DOI":"10.1136\/bmjopen-2018-026779"},{"key":"3142_CR96","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2005-07-2737","volume":"107","author":"G Zhou","year":"2006","unstructured":"Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628\u2013636","journal-title":"Blood"},{"key":"3142_CR97","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:400\u2013404","journal-title":"Nature"},{"key":"3142_CR98","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT et al (2019) Neoantigen-directed immune escape in lung cancer evolution. Nature 567:479\u2013485","journal-title":"Nature"},{"key":"3142_CR99","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.1073\/pnas.141226398","volume":"98","author":"L Fong","year":"2001","unstructured":"Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA et al (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 98:8809\u20138814","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3142_CR100","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00262-001-0257-z","volume":"51","author":"T Itoh","year":"2002","unstructured":"Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N et al (2002) Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother CII 51:99\u2013106","journal-title":"Cancer Immunol Immunother CII"},{"key":"3142_CR101","first-page":"909","volume":"24","author":"Y Ueda","year":"2004","unstructured":"Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y et al (2004) Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 24:909\u2013917","journal-title":"Int J Oncol"},{"key":"3142_CR102","first-page":"493","volume":"12","author":"K Kontani","year":"2003","unstructured":"Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S et al (2003) Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 12:493\u2013502","journal-title":"Int J Mol Med"},{"key":"3142_CR103","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","volume":"12","author":"SJ Antonia","year":"2006","unstructured":"Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N et al (2006) Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 12:878\u2013887","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3142_CR104","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1756-9966-30-65","volume":"30","author":"MW Perroud","year":"2011","unstructured":"Perroud MW, Honma HN, Barbeiro AS, Gilli SC, Almeida MT, Vassallo J et al (2011) Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study. J Exp Clin Cancer Res CR 30:65","journal-title":"J Exp Clin Cancer Res CR"},{"key":"3142_CR105","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1200\/JCO.2004.01.074","volume":"22","author":"EA Hirschowitz","year":"2004","unstructured":"Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J (2004) Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 22:2808\u20132815","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3142_CR106","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1186\/s12885-017-3859-3","volume":"17","author":"C Ge","year":"2017","unstructured":"Ge C, Li R, Song H, Geng T, Yang J, Tan Q et al (2017) Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC. BMC Cancer 17:884","journal-title":"BMC Cancer"},{"key":"3142_CR107","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-04-1453","volume":"11","author":"A Ishikawa","year":"2005","unstructured":"Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M et al (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 11:1910\u20131917","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3142_CR108","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13063-017-2103-4","volume":"18","author":"H Saka","year":"2017","unstructured":"Saka H, Kitagawa C, Ichinose Y, Takenoyama M, Ibata H, Kato T et al (2017) A randomized phase II study to assess the effect of adjuvant immunotherapy using \u03b1-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial. Trials 18:429","journal-title":"Trials"},{"key":"3142_CR109","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1158\/1078-0432.CCR-16-2821","volume":"23","author":"JM Lee","year":"2017","unstructured":"Lee JM, Lee M-H, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE et al (2017) Phase I trial of intratumoral injection of ccl21 gene-modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T-cell infiltration. Clin Cancer Res Off J Am Assoc Cancer Res 23:4556\u20134568","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"193","key":"3142_CR110","first-page":"1006","volume":"2014","author":"JM Pitt","year":"1950","unstructured":"Pitt JM, Charrier M, Viaud S, Andr\u00e9 F, Besse B, Chaput N et al (1950) Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol Baltim Md 2014(193):1006\u20131011","journal-title":"J Immunol Baltim Md"},{"key":"3142_CR111","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri3622","volume":"14","author":"PD Robbins","year":"2014","unstructured":"Robbins PD, Morelli AE (2014) Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 14:195\u2013208","journal-title":"Nat Rev Immunol"},{"key":"3142_CR112","doi-asserted-by":"crossref","unstructured":"Viaud S, Terme M, Flament C, Taieb J, Andr\u00e9 F, Novault S et al (2009) Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PloS One 4:e4942.","DOI":"10.1371\/journal.pone.0004942"},{"key":"3142_CR113","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-3-10","volume":"3","author":"B Escudier","year":"2005","unstructured":"Escudier B, Dorval T, Chaput N, Andr\u00e9 F, Caby M-P, Novault S et al (2005) Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med 3:10","journal-title":"J Transl Med"},{"key":"3142_CR114","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1479-5876-3-9","volume":"3","author":"MA Morse","year":"2005","unstructured":"Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM et al (2005) A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3:9","journal-title":"J Transl Med"},{"key":"3142_CR115","doi-asserted-by":"crossref","unstructured":"Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D et al  (2016)  Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 5:e1071008.","DOI":"10.1080\/2162402X.2015.1071008"},{"issue":"34","key":"3142_CR116","first-page":"65","volume":"2011","author":"S Viaud","year":"1997","unstructured":"Viaud S, Ploix S, Lapierre V, Th\u00e9ry C, Commere P-H, Tramalloni D et al (1997) Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-\u03b3. J Immunother Hagerstown Md 2011(34):65\u201375","journal-title":"J Immunother Hagerstown Md"},{"key":"3142_CR117","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00262-016-1872-z","volume":"65","author":"H Takahashi","year":"2016","unstructured":"Takahashi H, Shimodaira S, Ogasawara M, Ota S, Kobayashi M, Abe H et al (2016) Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis. Cancer Immunol Immunother CII 65:1099\u20131111","journal-title":"Cancer Immunol Immunother CII"},{"key":"3142_CR118","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1758834016678375","volume":"9","author":"K Teramoto","year":"2017","unstructured":"Teramoto K, Ozaki Y, Hanaoka J, Sawai S, Tezuka N, Fujino S et al (2017) Predictive biomarkers and effectiveness of MUC1-targeted dendritic-cell-based vaccine in patients with refractory non-small cell lung cancer. Ther Adv Med Oncol 9:147\u2013157","journal-title":"Ther Adv Med Oncol"},{"key":"3142_CR119","doi-asserted-by":"crossref","unstructured":"Manfredi F, Cianciotti BC, Potenza A, Tassi E, Noviello M, Biondi A et al (2020)TCR Redirected T Cells for cancer treatment: achievements, hurdles, and goals. Front Immunol [Internet]. 2020 [cited 2021 Apr 6];11. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7494743\/","DOI":"10.3389\/fimmu.2020.01689"},{"key":"3142_CR120","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71:5697\u20135706","journal-title":"Cancer Res"},{"key":"3142_CR121","doi-asserted-by":"crossref","unstructured":"Rath JA, Arber C (2020) Engineering strategies to enhance TCR-based adoptive T cell therapy. Cells [Internet]. 2020 [cited 2021 Apr 5];9. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7349724\/","DOI":"10.3390\/cells9061485"},{"key":"3142_CR122","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/nm.3910","volume":"21","author":"AP Rapoport","year":"2015","unstructured":"Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF et al (2015) NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med 21:914\u2013921","journal-title":"Nat Med"},{"key":"3142_CR123","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","volume":"29","author":"PF Robbins","year":"2011","unstructured":"Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol Off J Am Soc Clin Oncol 29:917\u2013924","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"3142_CR124","doi-asserted-by":"crossref","unstructured":"Creelan BC, Gainor JF, Govindan R, Hardy NM, Heymach J, Mudad R et al (2017) Two phase I\/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612\/NCT02592577). J Clin Oncol 35:TPS3096\u2013TPS3096.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3096"},{"key":"3142_CR125","doi-asserted-by":"publisher","unstructured":"Reckamp KL, Akerley W, Edelman MJ, Halmos B, He K, Johnson M et al (2019)  Abstract CT225: A Phase Ib\/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1\/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer. Clin Trials [Internet]. American Association for Cancer Research; 2019 [cited 2021 Mar 26]. p. CT225\u2013CT225. Available from: http:\/\/cancerres.aacrjournals.org\/lookup\/doi\/https:\/\/doi.org\/10.1158\/1538-7445.AM2019-CT225","DOI":"10.1158\/1538-7445.AM2019-CT225"},{"key":"3142_CR126","doi-asserted-by":"crossref","unstructured":"Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan D-AN, Feldman SA et al (2011)T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther J Am Soc Gene Ther 19:620\u2013626.","DOI":"10.1038\/mt.2010.272"},{"key":"3142_CR127","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114:535\u2013546","journal-title":"Blood"},{"key":"3142_CR128","doi-asserted-by":"crossref","unstructured":"Tsimberidou A-M, Ma H, Stewart C, Schoor O, Maurer D, Mendrzyk R et al (2018) Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog\u00ae IMA101) in patients with relapsed and\/or refractory solid cancers. Ann Oncol 29:viii411.","DOI":"10.1093\/annonc\/mdy288.028"},{"key":"3142_CR129","unstructured":"George R. Blumenschein AB (2021) The University of Texas MD Anderson Cancer Center H, Immatics US I, MD Anderson Cancer Center H. Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer\/germline antigen in patients with squamous NSCLC or HNSCC. [cited 2021 Mar 29]; Available from: https:\/\/meetinglibrary.asco.org\/record\/156705\/abstract"},{"key":"3142_CR130","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.copbio.2019.12.014","volume":"65","author":"M Arnaud","year":"2020","unstructured":"Arnaud M, Duchamp M, Bobisse S, Renaud P, Coukos G, Harari A (2020) Biotechnologies to tackle the challenge of neoantigen identification. Curr Opin Biotechnol 65:52\u201359","journal-title":"Curr Opin Biotechnol"},{"key":"3142_CR131","doi-asserted-by":"crossref","unstructured":"Gaissmaier L, Elshiaty M, Christopoulos P (2020) Breaking bottlenecks for the TCR therapy of cancer. Cells, 9.","DOI":"10.3390\/cells9092095"},{"key":"3142_CR132","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1038\/s41596-019-0170-6","volume":"14","author":"M Ali","year":"2019","unstructured":"Ali M, Foldvari Z, Giannakopoulou E, B\u00f6schen M-L, Str\u00f8nen E, Yang W et al (2019) Induction of neoantigen-reactive T cells from healthy donors. Nat Protoc 14:1926\u20131943","journal-title":"Nat Protoc"},{"key":"3142_CR133","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ et al (2018) Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559:405\u2013409","journal-title":"Nature"},{"key":"3142_CR134","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG et al (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122:4129\u20134139","journal-title":"Blood"},{"key":"3142_CR135","doi-asserted-by":"crossref","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al (2014) Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25.","DOI":"10.1126\/scitranslmed.3008226"},{"key":"#cr-split#-3142_CR136.1","unstructured":"Sj S, Mr B, Cs T, Ek W, P B, Jp M et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med [Internet]. N Engl J Med"},{"key":"#cr-split#-3142_CR136.2","unstructured":"2019 [cited 2021 Mar 25];380. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30501490\/"},{"key":"3142_CR137","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","volume":"21","author":"C Klein","year":"2021","unstructured":"Klein C, Jamois C, Nielsen T (2021) Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther 21:161\u2013181","journal-title":"Expert Opin Biol Ther"},{"key":"3142_CR138","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H (2015) TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15:1145\u20131154","journal-title":"Expert Opin Biol Ther"},{"key":"3142_CR139","doi-asserted-by":"crossref","unstructured":"Specht JM, Lee S, Turtle C, Berger C, Veatch J, Gooley T et al (2018) Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells. J Clin Oncol 36:TPS79\u2013TPS79.","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS79"},{"key":"3142_CR140","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","volume":"37","author":"PS Adusumilli","year":"2019","unstructured":"Adusumilli PS, Zauderer MG, Rusch VW, O\u2019Cearbhaill R, Zhu A, Ngai D et al (2019) Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent. J Clin Oncol 37:2511\u20132511","journal-title":"J Clin Oncol"},{"key":"3142_CR141","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","volume":"32","author":"S Hiltbrunner","year":"2021","unstructured":"Hiltbrunner S, Britschgi C, Schuberth P, Bankel L, Nguyen-Kim TDL, Gulati P et al (2021) Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Ann Oncol Off J Eur Soc Med Oncol 32:120\u2013121","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"3142_CR142","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G et al (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112\u2013120","journal-title":"Cancer Immunol Res"},{"key":"3142_CR143","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2217\/imt-2017-0062","volume":"9","author":"IB Riaz","year":"2017","unstructured":"Riaz IB, Zahid U, Kamal MU, Husnain M, McBride A, Hua A et al (2017) Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis. Immunotherapy 9:979\u2013993","journal-title":"Immunotherapy"},{"key":"3142_CR144","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.3389\/fimmu.2018.02740","volume":"9","author":"KB Long","year":"2018","unstructured":"Long KB, Young RM, Boesteanu AC, Davis MM, Melenhorst JJ, Lacey SF et al (2018) CAR T cell therapy of non-hematopoietic malignancies: detours on the road to clinical success. Front Immunol 9:2740","journal-title":"Front Immunol"},{"key":"3142_CR145","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","volume":"20","author":"EK Moon","year":"2014","unstructured":"Moon EK, Wang L-C, Dolfi DV, Wilson CB, Ranganathan R, Sun J et al (2014) Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 20:4262\u20134273","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"3142_CR146","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3389\/fimmu.2020.00702","volume":"11","author":"L Jafarzadeh","year":"2020","unstructured":"Jafarzadeh L, Masoumi E, Fallah-Mehrjardi K, Mirzaei HR, Hadjati J (2020) Prolonged Persistence of Chimeric Antigen Receptor (CAR) T cell in adoptive cancer immunotherapy: challenges and ways forward. Front Immunol 11:702","journal-title":"Front Immunol"},{"key":"3142_CR147","doi-asserted-by":"crossref","unstructured":"McLellan AD, Ali Hosseini Rad SM (2019) Chimeric antigen receptor T cell persistence and memory cell formation. Immunol Cell Biol 97:664\u2013674.","DOI":"10.1111\/imcb.12254"},{"key":"3142_CR148","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11427-016-5023-8","volume":"59","author":"K Feng","year":"2016","unstructured":"Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H et al (2016) Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed\/refractory non-small cell lung cancer. Sci China Life Sci 59:468\u2013479","journal-title":"Sci China Life Sci"},{"key":"3142_CR149","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS et al (2021) Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell 39:193-208.e10","journal-title":"Cancer Cell"},{"key":"3142_CR150","doi-asserted-by":"crossref","unstructured":"Liu H, Ma Y, Yang C, Xia S, Pan Q, Zhao H et al (2020) Severe delayed pulmonary toxicity following PD-L1-specific CAR-T cell therapy for non-small cell lung cancer. Clin Transl Immunol 9:e1154.","DOI":"10.1002\/cti2.1154"},{"key":"3142_CR151","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","volume":"27","author":"AR Haas","year":"2019","unstructured":"Haas AR, Tanyi JL, O\u2019Hara MH, Gladney WL, Lacey SF, Torigian DA et al (2019) Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers. Mol Ther J Am Soc Gene Ther 27:1919\u20131929","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"3142_CR152","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","volume":"37","author":"DT Harris","year":"2016","unstructured":"Harris DT, Kranz DM (2016) Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci 37:220\u2013230","journal-title":"Trends Pharmacol Sci"},{"key":"3142_CR153","doi-asserted-by":"crossref","unstructured":"Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ, Katovich Hurley C (2000) Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. Hum Immunol 61:334\u201340.","DOI":"10.1016\/S0198-8859(99)00155-X"},{"key":"3142_CR154","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1089\/hum.2012.030","volume":"23","author":"KM Kaluza","year":"2012","unstructured":"Kaluza KM, Kottke T, Diaz RM, Rommelfanger D, Thompson J, Vile R (2012) Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum Gene Ther 23:1054\u20131064","journal-title":"Hum Gene Ther"},{"key":"3142_CR155","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ebiom.2019.01.031","volume":"40","author":"N Mensali","year":"2019","unstructured":"Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR et al (2019) NK cells specifically TCR-dressed to kill cancer cells. EBioMedicine 40:106\u2013117","journal-title":"EBioMedicine"},{"key":"3142_CR156","doi-asserted-by":"crossref","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J (2020) CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine 59:102975.","DOI":"10.1016\/j.ebiom.2020.102975"},{"key":"3142_CR157","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/238924","volume":"2012","author":"C Schlimper","year":"2012","unstructured":"Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IGH (2012) Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012:1\u20138","journal-title":"Clin Dev Immunol"},{"key":"3142_CR158","doi-asserted-by":"crossref","unstructured":"Leuci V, Casucci M, Grignani G, Rotolo R, Rossotti U, Vigna E et al (2018) CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. OncoImmunology 7:e1423167.","DOI":"10.1080\/2162402X.2017.1423167"},{"key":"3142_CR159","doi-asserted-by":"crossref","unstructured":"Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina J  et al (2011) Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res Off J Am Assoc Cancer Res 17:4719\u20134730.","DOI":"10.1158\/1078-0432.CCR-11-0351"},{"key":"3142_CR160","doi-asserted-by":"crossref","unstructured":"Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J et al (2014) Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6:261ra151.","DOI":"10.1126\/scitranslmed.3010162"},{"key":"3142_CR161","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1172\/JCI58814","volume":"121","author":"SP Kerkar","year":"2011","unstructured":"Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN et al (2011) IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 121:4746\u20134757","journal-title":"J Clin Invest"},{"key":"3142_CR162","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1365-2567.2011.03429.x","volume":"133","author":"CE Steding","year":"2011","unstructured":"Steding CE, Wu S, Zhang Y, Jeng M-H, Elzey BD, Kao C (2011) The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 133:221\u2013238","journal-title":"Immunology"},{"key":"3142_CR163","doi-asserted-by":"crossref","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E et al (2020) CRISPR-engineered T cells in patients with refractory cancer. Science, p 367.","DOI":"10.1126\/science.aba7365"},{"key":"3142_CR164","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","volume":"26","author":"Y Lu","year":"2020","unstructured":"Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L et al (2020) Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med 26:732\u2013740","journal-title":"Nat Med"},{"key":"3142_CR165","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S et al (2016) A Chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res 76:1578\u20131590","journal-title":"Cancer Res"},{"key":"3142_CR166","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/CMR.0000000000000436","volume":"28","author":"KC Foley","year":"2018","unstructured":"Foley KC, Nishimura MI, Moore TV (2018) Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. Melanoma Res 28:171\u2013184","journal-title":"Melanoma Res"},{"issue":"189","key":"3142_CR167","first-page":"5147","volume":"2012","author":"KN Kodumudi","year":"1950","unstructured":"Kodumudi KN, Weber A, Sarnaik AA, Pilon-Thomas S (1950) Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol Baltim Md 2012(189):5147\u20135154","journal-title":"J Immunol Baltim Md"},{"key":"3142_CR168","doi-asserted-by":"crossref","unstructured":"Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK (2013) Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2:e25962.","DOI":"10.4161\/onci.25962"},{"key":"3142_CR169","first-page":"2505","volume":"31","author":"T Morisaki","year":"2011","unstructured":"Morisaki T, Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M et al (2011) Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA\/B system. Anticancer Res 31:2505\u20132510","journal-title":"Anticancer Res"},{"key":"3142_CR170","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist N-P, Golden E, Cooper B, Wennerberg E, Lhuillier C et al (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24:1845\u20131851","journal-title":"Nat Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03142-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03142-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T12:06:22Z","timestamp":1660305982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03142-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":171,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3142"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03142-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"4 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}